EDAP TMS Publishes HIFI Study Results In European Urology
EDAP TMS Publishes HIFI Study Results In European Urology
edap tms 在《歐洲泌尿學》上發佈HIFI研究結果
- HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatments
- Positive study results are expected to drive further adoption of Focal One as a first line treatment option for the management of localized prostate cancer
- Study shows Focal One Robotic HIFU is non-inferior to surgery, meeting primary endpoint of non-inferiority for Salvage Treatment-free Survival (STFS) after High Intensity Focused Ultrasounds (HIFU) compared to Radical Prostatectomy (RP) at 30 months
- Study shows that patients receiving HIFU had better outcomes with respect to urinary continence and erectile function compared to patients receiving RP
- HiFi Study是有史以來最大規模（N = 3,328）的前瞻性、比較性、多中心臨床研究，旨在比較前列腺癌治療方法。
- 積極的研究結果預計將推動更多人選擇Focal One作爲管理侷限性前列腺癌的第一線治療方案。
- 研究表明，Focal One機器人輔助高強度聚焦超聲（HIFU）不劣於手術，滿足了在高強度聚焦超聲（HIFU）後與在根治性前列腺切除術（RP）後30個月的救助治療無進展生存（STFS）方面的非劣效性主要終點。
- 研究表明，接受HIFU治療的患者在尿瀦留和勃起功能方面的結果優於接受RP治療的患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間